Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

International Prize for VTT's Allergy Vaccine Development Work

Published: Monday, December 09, 2013
Last Updated: Sunday, December 08, 2013
Bookmark and Share
First vaccines to be ready for launch in about five years.

The European Association of Research and Technology Organizations EARTO has awarded VTT Technical Research Centre of Finland an innovation prize for the technological development work behind allergy vaccine.

VTT patented technology helps the human body to develop resistance to allergens. The award ceremony was held in Brussels on Wednesday 4 December. VTT also has last year's EARTO innovation prize for its bio-oil production process.

VTT spin-off Desentum Ltd is responsible for developing and commercializing new generation allergy vaccines based on VTT technology. The first vaccines will be ready for launch in about five years.

“The innovation behind the allergy vaccine is a good example of just how significant the impact of science and technology on society can be. This is the second time EARTO has awarded VTT its innovation prize. Considering EARTO has around 300 member organizations, winning the prize in two consecutive years speaks volumes for the high level and impact of our research and development work,” says Johanna Buchert, Vice President, Strategic Research, VTT.

VTT's patents are based on application of gene technology to alter the structure of an allergen - a protein causing allergy – so that it will cause fewer allergic symptoms while remaining effective in desensitization therapy.

The foundation for the development work rests on a scientific breakthrough made in a cooperation project involving VTT, the University of Eastern Finland and HUCH Skin and Allergy Hospital.

Research scientists were able to determine how an IgE antibody binds an allergen, and were the first to present a detailed 3D structure. The complex proved to be different from that anticipated by scientists around the world.

Desentum Ltd, the VTT spin-off responsible for the development and commercialization of the allergy vaccine, plans to start phase I clinical trials within a year. The first allergy vaccines could enter the market in about five years. These are expected to alleviate the symptoms of common allergies such as pollen, animal and food allergies.

According to estimates, allergies are among the top five costliest disease groups in industrialized countries. The estimated number of people suffering from allergies in Europe is more than 80 million, with 65 million in the US.

Allergic rhinitis affects around 25 per cent of the European population. The estimated market for the new allergy vaccines is approximately EUR 366 million in Europe and approximately USD 700–800 million worldwide.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

VTT Printed a Morphine Test on Paper
Company use antibodies as morphine sensing molecules when creating this morphine test.
Saturday, April 18, 2015
European Research Project Aims at Early Diagnosis of Memory Disorders
800 patients to participate in testing new diagnostic procedures.
Thursday, March 20, 2014
Novel Cancer Cell DNA Damage Repair Mechanism
Findings result from application of the cell microarray screening method developed at VTT.
Monday, December 23, 2013
Powerful Enzymes Create Ethanol from Agricultural Harvest Waste
The mainly EU-funded DISCO project coordinated by VTT Technical Research Centre of Finland has developed powerful enzymes, which accelerate plant biomass conversion into sugars and further into products such as bioethanol.
Wednesday, January 09, 2013
Method Developed by VTT Targets Diagnosis of Early Alzheimer’s Disease
Half of patients could be diagnosed a year earlier than current clinical practice.
Friday, December 07, 2012
Food Industry’s High-Quality Co-Streams Used Effectively as Raw Material for New Products
Researchers develop new ways of using substantial co-streams from fish and oil plant processing.
Tuesday, August 14, 2012
VTT and GE Healthcare Developing Novel Biomarkers to Predict Alzheimer’s Disease
VTT and University of Eastern Finland scientists have discovered a serum biochemical signature.
Wednesday, June 27, 2012
Heparin-like Compounds Inhibit Breast Cancer Metastasis to Bone
Heparin-like compounds decreased bone destruction and tumor growth in bone.
Friday, June 15, 2012
VTT Identified Specific Bacteria which Precede Autoimmune Diabetes
New potential avenues for early disease detection and prevention.
Friday, October 28, 2011
Finnish Twin Study Yields New Information on How Fat Cells Cope With Obesity
The team used lipidomics to study the fat tissue biopsies among several sets of monozygotic twins.
Friday, July 29, 2011
One Step Closer to a Diagnostic Test for Schizophrenia
Scientists in Finland have revealed metabolic abnormalities that are associated with schizophrenia.
Thursday, April 14, 2011
VTT is Searching for New Drug Targets for Prostate Cancer in the New IMI PREDECT Project
PREDECT, one of IMI’s new projects, is developing novel models for breast, prostate and lung cancers.
Monday, April 04, 2011
New Potential Drug Targets Discovered for Preventing Prostate Cancer Cell Growth
Researchers from VTT Technical Research Centre of Finland and the University of Turku have discovered four metabolic enzymes regulating prostate cancer cell growth.
Friday, February 18, 2011
Zora Biosciences Commercializes VTT's Biotechnology Expertise
Zora will provide laboratory services to pharmaceutical industry in the area of metabolomics and associated bioinformatics.
Wednesday, June 27, 2007
VTT Develops Software Tool to Integrate and Analyze Complex Medical Data
The megNet® software can be applied in understanding complex relations in living organisms, and characterizing various diseases, such as cardiac diseases and diabetes.
Friday, April 27, 2007
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
Scientists Find Evidence That Cancer Can Arise Changes
Researchers at Rockefeller University have found a mutation that affects the proteins that package DNA without changing the DNA itself can cause a rare form of cancer.
Developing a More Precise Seasonal Flu Vaccine
During the 2014-15 flu season, the poor match between the virus used to make the world’s vaccine stocks and the circulating seasonal virus yielded a vaccine that was less than 20 percent effective.
A Peachy Defense System for Seeds
ETH chemists are developing a new coating method to protect seeds from being eaten by insects. In doing so, they have drawn inspiration from the humble peach and a few of its peers.
Fighting Cancer with Borrowed Immunity
A new step in cancer immunotherapy: researchers from the Netherlands Cancer Institute and University of Oslo/Oslo University Hospital show that even if one's own immune cells cannot recognize and fight their tumors, someone else's immune cells might.
Modified Microalgae Converts Sunlight into Valuable Medicine
A special type of microalgae can soon produce valuable chemicals such as cancer treatment drugs and much more just by harnessing energy from the sun.
Breakthrough Approach to Breast Cancer Treatment
Scripps scientists have designed a drug candidate that decreases growth of breast cancer cells.
Loss Of Y Chromosome Increases Risk Of Alzheimer’s
Men with blood cells that do not carry the Y chromosome are at greater risk of being diagnosed with Alzheimer’s disease. This is in addition to an increased risk of death from other causes, including many cancers. These new findings by researchers at Uppsala University could lead to a simple test to identify those at risk of developing Alzheimer’s disease.
Making Virus Sensors Cheap and Simple
Researchers at The University of Texas at Austin demonstrated the ability to detect single viruses in a solution containing murine cytomegalovirus (MCMV).
A Guide to CRISPR Gene Activation
A comparison of synthetic gene-activating Cas9 proteins can help guide research and development of therapeutic approaches.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!